Skip to main content

and
  1. Article

    Open Access

    A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis

    Non-alcoholic steatohepatitis (NASH) is a progressive, inflammatory liver disease with no approved pharmacological treatment. This Phase IIa, double-blind, placebo-controlled, multicentre trial (ClinicalTrials...

    Philip N. Newsome, Arun J. Sanyal, Guy Neff, Jörn M. Schattenberg in Nature Communications (2023)

  2. Article

    Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

    Preclinical and clinical data suggest that fibroblast growth factor 21 (FGF21) is anti-fibrotic, improves metabolic status and has potential to treat non-alcoholic steatohepatitis (NASH). We assessed the safet...

    Stephen A. Harrison, Peter J. Ruane, Bradley L. Freilich, Guy Neff in Nature Medicine (2021)

  3. Article

    Open Access

    Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

    The article Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin written by Guy Neff, Woodie Zachry was originally published electronically on the p...

    Guy Neff, Woodie Zachry III in PharmacoEconomics (2018)

  4. Article

    Open Access

    Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

    Hepatic encephalopathy (HE), a common neurologic complication in cirrhosis, is associated with substantial disease and economic burden. Rifaximin is a non-systemic antibiotic that reduces the risk of overt HE ...

    Guy Neff, Woodie Zachry III in PharmacoEconomics (2018)

  5. No Access

    Article

    Therapy related CMML: a case report and review of the literature

    Therapy related chronic myelomonocytic leukemia (t-CMML) is rare. We report a 23-year-old female who developed acute fulminant hepatic failure after drug overdose. She underwent ABO incompatible orthotopic liv...

    Faheem Ahmed, Nadia Osman, Fred Lucas, Guy Neff in International Journal of Hematology (2009)

  6. No Access

    Article

    Ethnic Differences in Hepatocellular Carcinoma: Implications for Liver Transplantation

    Liver transplantation (LT) as a treatment for Hepatocellular Carcinoma (HCC) provides excellent outcomes if restricted to patients who meet the Milan criteria (MC). The aim of this study was to evaluate the in...

    Nyingi Kemmer, Guy Neff, Michelle Secic in Digestive Diseases and Sciences (2008)

  7. No Access

    Article

    Suspected Biliary Complications After Laparoscopic and Open Cholecystectomy Leading to Endoscopic Cholangiography A Retrospective Comparison

    To study how suspected postoperative biliarycomplications are influenced by surgical technique, wecompared clinical profiles of 63 patients referred forERCP after open (OC) and laparoscopic cholecystectomy (LC...

    Charles F. Gholson, Craig Dungan, Guy Neff in Digestive Diseases and Sciences (1998)